Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBIO123
- Development stage
- Phase 2
- Lead developer
- Immune Biosolutions
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Inhalation
01
Overview
**IBIO123** is an investigational inhaled fixed-dose cocktail of three fully human recombinant neutralizing monoclonal antibodies developed by Immune Biosolutions for treatment and post-exposure prophylaxis of COVID-19. The antibodies bind distinct regions of the SARS-CoV-2 spike glycoprotein, aiming to neutralize viral entry directly in the respiratory tract following nebulized inhalation. Phase 1/2 studies evaluated IBIO123 in mild-to-moderate and severe COVID-19, and a Phase 2 study evaluated post-exposure prophylaxis in household contacts. ([europepmc.org](https://europepmc.org/article/MED/37619584))
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on IBIO123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBIO123.